Precision BioSciencesDTIL -4.37%50 ROC (Joel Greenblatt) % is -1,400.68% as of Mar. 2026. GuruFocus rates DTIL with a GF Score™ of 50/100 and a GF Value™ of $1.83 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,320 Biotechnology companies, Precision BioSciences ranks worse than 59.77% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Precision BioSciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -1,400.68%.
The historical rank and industry rank for Precision BioSciences's ROC (Joel Greenblatt) % or its related term are showing as below:
DTIL'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -585.14 Med: -283.98 Max: 72.23
Current: -585.14
During the past 9 years, Precision BioSciences's highest ROC (Joel Greenblatt) % was 72.23%. The lowest was -585.14%. And the median was -283.98%.
DTIL's ROC (Joel Greenblatt) % is ranked worse than 59.77% of 1320
companies
in the Biotechnology industry
Industry Median: -294.23
vs DTIL: -585.14
Precision BioSciences's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Precision BioSciences ROC (Joel Greenblatt) % Related Terms
Precision BioSciences ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Precision BioSciences's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DTIL vs NBP, HUMA, ORMP: ROC (Joel Greenblatt) % Comparison
For the Biotechnology subindustry, Precision BioSciences's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Precision BioSciences ROC (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Precision BioSciences's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Precision BioSciences's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of -1,400.68% mean?
Precision BioSciences (DTIL) has a ROC (Joel Greenblatt) % of -1,400.68% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Precision BioSciences and its competitors. According to the industry distribution chart, Precision BioSciences ranks #789 out of 1320 companies in the Biotechnology industry, placing it in the top 59.8%.
Is Precision BioSciences' ROC (Joel Greenblatt) % too high?
Precision BioSciences' current ROC (Joel Greenblatt) % is -1,400.68%. Based on the distribution chart, Precision BioSciences ranks #789 out of 1320 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Precision BioSciences has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Precision BioSciences' ROC (Joel Greenblatt) % compare to NBP and HUMA?
According to the Biotechnology industry distribution chart, Precision BioSciences ranks #789 out of 1320 companies for ROC (Joel Greenblatt) %. This places Precision BioSciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Precision BioSciences and its competitors. Precision BioSciences's current ROC (Joel Greenblatt) % is -1,400.68%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Precision BioSciences stock overvalued right now?
Based on GuruFocus' analysis, Precision BioSciences (DTIL) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.83, compared to a current price of $8.77 — trading 379% above its estimated fair value. The current ROC (Joel Greenblatt) % is -1,400.68%. Precision BioSciences' overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Precision BioSciences (DTIL), the current ROC (Joel Greenblatt) % is -1,400.68% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Precision BioSciences (DTIL) Overvalued in 2026?
Based on GuruFocus' analysis, Precision BioSciences stock appears to be overvalued.
The current stock price of $8.77 is trading 379% above its estimated GF Value™ of $1.83.
GuruFocus considers Precision BioSciences to be Significantly Overvalued.
Key valuation signals for DTIL:
ROC (Joel Greenblatt) %: -1,400.68%
GF Value™: $1.83 vs. price of $8.77 (379% above fair value)
No single metric tells the full story. See the DTIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
50GF Score
Get the complete analysis for DTIL
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DTIL has been successfully added to your 
